Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

La‐Beck, Ninh M.; Liu, Xinli; Shmeeda, Hilary; Shudde, Claire E; Gabizón, Alberto

doi:10.1016/j.semcancer.2019.12.001

Cited by 30 publications

(36 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These proteins are necessary for the binding and presentation of phosphates to Vδ2T cells, driving their activation [ 195 , 196 , 197 ]. For this immunostimulating property, besides the direct anti-cancer effects, different N-BPs have been employed in clinical trials [ 198 , 199 , 200 ].…”

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

“…The main pharmacokinetic features of N-BPs are their rapid clearance from the circulation and a specific bone tropism [ 200 , 201 , 202 , 203 ]. Indeed, these drugs are used to treat osteoporosis, due to their activity on osteocytes favouring bone matrix deposition [ 203 , 204 ].…”

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

“…Indeed, these drugs are used to treat osteoporosis, due to their activity on osteocytes favouring bone matrix deposition [ 203 , 204 ]. This is the major drawback of N-BPs because the activation of Vδ2T cells could take place mostly within the bone, excluding other possible tumor sites when free drug formulations are used [ 200 ]. This property can be useful for the treatment of tumor bone metastasis, or primary bone tumors, such as MM [ 205 ].…”

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

“…For EV, simple purification protocols and specific localization to tumor cells are still open issues. In addition, while lipophilic molecules can directly enter the EV lipid bilayer, hydrophilic molecules must be carried into EV by mechanical or chemical procedures that may reduce EV quality [ 200 ]. Bridging molecules, RNA aptamers, and chimeras are presently applied to optimize targeting and enhance the effectiveness of EV [ 69 , 76 ], specific engineering of EV surface remaining the most substantial approach.…”

Section: Challenges For Clinical Implementationmentioning

confidence: 99%

“…( A ) Main features of non-amino and amino bisphosphonates are reviewed in Ref. [ 200 ]. ( B ) Non-N and N-BPs employed as free drugs or as liposome (L) or nanoparticles (NPs) to inhibit tumor cell growth.…”

Section: Figurementioning

confidence: 99%

See 4 more Smart Citations

Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy

Zocchi

Tosetti

Benelli

et al. 2020

Cancers

View full text Add to dashboard Cite

Both natural and synthetic nanoparticles have been proposed as drug carriers in cancer treatment, since they can increase drug accumulation in target tissues, optimizing the therapeutic effect. As an example, extracellular vesicles (EV), including exosomes (Exo), can become drug vehicles through endogenous or exogenous loading, amplifying the anticancer effects at the tumor site. In turn, synthetic nanoparticles (NP) can carry therapeutic molecules inside their core, improving solubility and stability, preventing degradation, and controlling their release. In this review, we summarize the recent advances in nanotechnology applied for theranostic use, distinguishing between passive and active targeting of these vehicles. In addition, examples of these models are reported: EV as transporters of conventional anticancer drugs; Exo or NP as carriers of small molecules that induce an anti-tumor immune response. Finally, we focus on two types of nanoparticles used to stimulate an anticancer immune response: Exo carried with A Disintegrin And Metalloprotease-10 inhibitors and NP loaded with aminobisphosphonates. The former would reduce the release of decoy ligands that impair tumor cell recognition, while the latter would activate the peculiar anti-tumor response exerted by γδ T cells, creating a bridge between innate and adaptive immunity.

show abstract

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

Section: Nanoformulated Aminobisphosphonates (N-bps) As Anti-cancementioning

confidence: 99%

Section: Challenges For Clinical Implementationmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy

Zocchi

Tosetti

Benelli

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

Effective γδ T‐cell clinical therapies: current limitations and future perspectives for cancer immunotherapy

Revesz,

Joyce,

Ebert

et al. 2024

Clin & Trans Imm

View full text Add to dashboard Cite

Abstractγδ T cells are a unique subset of T lymphocytes, exhibiting features of both innate and adaptive immune cells and are involved with cancer immunosurveillance. They present an attractive alternative to conventional T cell‐based immunotherapy due, in large part, to their lack of major histocompatibility (MHC) restriction and ability to secrete high levels of cytokines with well‐known anti‐tumour functions. To date, clinical trials using γδ T cell‐based immunotherapy for a range of haematological and solid cancers have yielded limited success compared with in vitro studies. This inability to translate the efficacy of γδ T‐cell therapies from preclinical to clinical trials is attributed to a combination of several factors, e.g. γδ T‐cell agonists that are commonly used to stimulate populations of these cells have limited cellular uptake yet rely on intracellular mechanisms; administered γδ T cells display low levels of tumour‐infiltration; and there is a gap in the understanding of γδ T‐cell inhibitory receptors. This review explores the discrepancy between γδ T‐cell clinical and preclinical performance and offers viable avenues to overcome these obstacles. Using more direct γδ T‐cell agonists, encapsulating these agonists into lipid nanocarriers to improve their pharmacokinetic and pharmacodynamic profiles and the use of combination therapies to overcome checkpoint inhibition and T‐cell exhaustion are ways to bridge the gap between preclinical and clinical success. Given the ability to overcome these limitations, the development of a more targeted γδ T‐cell agonist‐checkpoint blockade combination therapy has the potential for success in clinical trials which has to date remained elusive.

show abstract

Phytosomes Used for Herbal Drug Delivery

Saleemi

Lim

2022

Nanotechnology in the Life Sciences

View full text Add to dashboard Cite

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Cited by 30 publications

References 99 publications

Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy

Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy

Effective γδ T‐cell clinical therapies: current limitations and future perspectives for cancer immunotherapy

Phytosomes Used for Herbal Drug Delivery

Contact Info

Product

Resources

About